Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony histologicznie lub cytologicznie rak trzustki typu przewodowego
- •Ogólny stan zdrowia na poziomie umożliwiającym leczenie (ECOG ≤2)
- •Możliwość poddania się połączonemu leczeniu (operacja, radioterapia, zabiegi ablacyjne) wszystkich ognisk raka
- •Od 1 do 5 przerzutów oddalonych, które można poddać lokalnej terapii
- •Przerzuty mogą być w węzłach chłonnych albo w innych organach, pod warunkiem że można je leczyć lokalnie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Cooper Hospital University Medical Center
Camden, United States
Cooper Hospital University Medical Center
Voorhees Township, United States
University of Texas Southwestern Medical Center
Dallas, United States
MD Anderson Cancer Center
Houston, United States
Trial contact
Ethan Ludmir, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.